SCHEMBL17656103

SCHEMBL17656103

Cc1nc(-c2nnc3n2CCN(N)[C@@H]3C)c(C)s1

nearest known ligand 0.49

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 20/20 0.49
CYP2C9 P11712 5/20 0.33
CYP2C19 P33261 5/20 0.33
CYP3A4 P08684 4/20 0.33
KCNH2 Q12809 8/20 0.32
ERG P11308 1/20 0.32
CYP1A2 P05177 3/20 0.32
TACR1 P25103 2/20 0.31
CYP2D6 P10635 1/20 0.31
TACR2 P21452 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14850731 1.00 TACR3 (0.49) TACR3CYP2C9CYP2C19CYP3A4KCNH2
SCHEMBL14850683 0.78 TACR3 (0.49) TACR3CYP2C9CYP2C19CYP3A4KCNH2
SCHEMBL14844333 0.75 TACR3 (0.52) TACR3
SCHEMBL14844508 0.75 TACR3 (0.52) TACR3
SCHEMBL14850676 0.72 TACR3 (0.57) TACR3CYP2C9CYP2C19CYP3A4KCNH2
SCHEMBL17656121 0.72 TACR3 (0.57) TACR3CYP2C9CYP2C19CYP3A4KCNH2
SCHEMBL14850792 0.71 TACR3 (0.54) TACR3CYP2C9CYP2C19CYP3A4KCNH2
SCHEMBL17656127 0.69 TACR3 (0.56) TACR3CYP2C9CYP2C19CYP3A4KCNH2
SCHEMBL14850675 0.69 TACR3 (0.56) TACR3CYP2C9CYP2C19CYP3A4KCNH2
SCHEMBL14850789 0.69 TACR3 (0.54) TACR3CYP2C9CYP2C19CYP3A4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2763992-B9 NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, AND METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS EUROSCREEN SA (BE) 2016-08-24 EP disclosed
EP-2763992-B1 NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, AND METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS EUROSCREEN SA (BE) 2016-04-06 EP disclosed